- Ares Genetics selected for NVIDIA and AWS programs to
accelerate commercialization of its AI-powered Universal
Pathogenome Assay – ARESupa
- NVIDIA Inception program accelerates start-ups that
revolutionize industries with advancements in AI
Vienna, Austria, and Holzgerlingen,
Germany, December 10, 2019, 08:00 am CET - Curetis N.V.
(the "Company" and, together with its
subsidiaries, "Curetis"), a developer of next-level molecular
diagnostic solutions, today announced that its fully-owned
subsidiary Ares Genetics has joined the NVIDIA Inception program as
a community member. The Inception program is designed to nurture
start-ups revolutionizing industries with advancements in AI and
data sciences. This virtual accelerator offers go-to-market
support, expertise, and technology for program members through deep
learning training, exclusive Inception events, and GPU
discounts.
The Company further announced that it has been
selected for the AWS Activate program, under which Amazon Web
Services (AWS) provides portfolio start-ups with the resources they
need to quickly start and scale their digital businesses on AWS.
Under the AWS Activate program, Ares Genetics will receive cloud
computing credits, training, and support to accelerate development
and commercialization of its AI-powered ARESupa.
NVIDIA is partnering with AWS to provide
leading-edge infrastructure to start-ups so they can innovate and
grow. Members of either company’s start-up program — NVIDIA
Inception or AWS Activate — are eligible to receive benefits
provided by the other.
Ares Genetics is a digital diagnostics company
utilizing AI-powered molecular diagnostics to advance the field of
infectious disease testing. The Company has recently launched the
ARESupa - Universal Pathogenome Assay, an award-winning tool for
personalized antibiotic susceptibility prediction combining
next-generation sequencing with AI. ARESupa is based on
whole-genome sequencing of bacterial strains isolated from clinical
specimens, combined with data analysis and interpretation powered
by ARESdb, Ares Genetics’ unique, proprietary reference database on
genetic antimicrobial resistance markers. ARESdb covers genomes of
about 40,000 bacterial strains and associated susceptibility data
for more than 100 different antibiotics. Currently under
development is an ARESupa laboratory-developed test on native
patient samples for human diagnostic use in indications in which
current culture-based diagnostic practice is inherently
challenging. Additionally, the Company has teamed up with Sandoz
and launched a pharma partnering program in December 2018 to
support drug development and life cycle management via a digital
anti-infectives platform combining established microbiology
laboratory methods with advanced bioinformatics and AI methods.
“We are proud that the further development and
commercialization of our AI-powered solutions for infectious
disease diagnostics and therapeutics will be supported by two of
the world’s leading companies in AI, data-driven solutions, and
cloud computing,” commented Dr. Andreas Posch, Managing Director
and CEO of Ares Genetics. “Already today, we support various
leading customers in the healthcare and pharma industry with our
ARESupa test and are currently working on globally scaling our
business via our cloud-based interpretation platform.”
###
About ARESupa Universal Pathogenome Assay
Information on antibiotic susceptibility of
pathogens is of utmost importance for clinical practice,
epidemiology and public health purposes as well as for the
development of pharmaceutical products in the infectious disease
sector. Ares Genetics therefore has developed a molecular
Antibiotic Susceptibility Test (AST) that is marketed under the
brand name ARESupa – Universal Pathogenome Assay and is capable of
accurately identifying microbial pathogens as well as predicting
antibiotic susceptibility via artificial intelligence-powered
interpretation of high-throughput DNA sequencing data obtained by
next-generation sequencing technologies.
ARESupa is based on whole-genome sequencing of
bacterial strains isolated from clinical specimens, combined with
data analysis and interpretation powered by ARESdb, Ares Genetics’
unique, proprietary reference database on genetic antimicrobial
resistance markers. ARESdb covers genomes of about 40,000 bacterial
strains and associated susceptibility data for more than 100
different antibiotics.
ARESupa already today performs in line with FDA
requirements for over 50 drug/pathogen combinations with prediction
algorithms for further drug/pathogen combinations in
development.
The test is initially offered for non-diagnostic
applications in epidemiology, infection control, and outbreak
analysis for customers in the public health sector and the
pharmaceutical industry. A laboratory-developed test (LDT) on
native patient samples for human diagnostic use in indications in
which current culture-based diagnostic practice is inherently
challenging is planned. Furthermore, Ares Genetics has recently
entered into a multi-phase strategic partnership with an
undisclosed leading global in vitro diagnostics corporation to
jointly develop diagnostic solutions for infectious disease testing
based on the ARESupa.
For further information and quotes, please register on the Ares
Genetics cloud platform:
https://ares-genetics.cloud/
or contact
Ares Genetics GmbHKarl-Farkas-Gasse 18A-1030
WienAustriaEmail: services@ares-genetics.com
About Curetis and Ares Genetics
Curetis N.V.’s (Euronext: CURE) goal is to
become a leading provider of innovative solutions for molecular
microbiology diagnostics designed to address the global challenge
of detecting severe infectious diseases and identifying antibiotic
resistances in hospitalized patients.
Curetis’ Unyvero System is a versatile, fast and
highly automated molecular diagnostic platform for easy-to-use,
cartridge-based solutions for the comprehensive and rapid detection
of pathogens and antimicrobial resistance markers in a range of
severe infectious disease indications. Results are available within
hours, a process that can take days or even weeks if performed with
standard diagnostic procedures, thereby facilitating improved
patient outcomes, stringent antibiotic stewardship and
health-economic benefits. Unyvero in vitro diagnostic (IVD)
products are marketed in Europe, the Middle East, Asia and the
U.S.
Curetis’ wholly owned subsidiary Ares Genetics
GmbH is developing next-generation solutions for infectious disease
diagnostics and therapeutics. The ARES Technology Platform combines
the presumably most comprehensive database worldwide on the
genetics of antimicrobial resistances, ARESdb, with advanced
bioinformatics and artificial intelligence.
For further information, please visit
www.curetis.com and www.ares-genetics.com.
Legal Disclaimer
This document constitutes neither an offer to
buy nor to subscribe securities and neither this document nor any
part of it should form the basis of any investment decision in
Curetis.
The information contained in this press release
has been carefully prepared. However, Curetis bears and assumes no
liability of whatever kind for the correctness and completeness of
the information provided herein. Curetis does not assume an
obligation of whatever kind to update or correct information
contained in this press release whether as a result of new
information, future events or for other reasons.
This press release includes statements that are,
or may be deemed to be, “forward-looking statements”. These
forward-looking statements can be identified by the use of
forward-looking terminology, including the terms “believes”,
“estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, or
“should”, and include statements Curetis makes concerning the
intended results of its strategy. By their nature, forward-looking
statements involve risks and uncertainties and readers are
cautioned that any such forward-looking statements are not
guarantees of future performance. Curetis’ actual results may
differ materially from those predicted by the forward-looking
statements. Curetis undertakes no obligation to publicly update or
revise forward-looking statements, except as may be required by
law.
Contact Details
Curetis GmbHMax-Eyth-Str.
4271088 Holzgerlingen, GermanyTel. +49 7031 49195-10pr@curetis.com
or ir@curetis.comwww.curetis.com
Curetis International Media &
Investor Inquiries
akampionDr. Ludger Wess / Ines-Regina
ButhManaging Partnersinfo@akampion.comTel. +49 40 88 16 59 64Tel.
+49 30 23 63 27 68
- 20191210_Ares_Inception_AWS_FINAL_Approved
Direxion Daily Healthcar... (AMEX:CURE)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Direxion Daily Healthcar... (AMEX:CURE)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024
